Yasmin Tayag

When the weather turns frigid, there is only one thing to do: make a pot of chicken-noodle soup. On the first cold afternoon in early December, I simmered a whole rotisserie chicken with fennel, dill, and orzo, then ladled it into bowls for a cozy family meal. Just as I thought we’d reached peak hygge, my five-month-old son suddenly grabbed my steaming bowl and tipped the soup all over himself. Piercing screams and a frenzied taxi ride to the pediatric emergency room ensued.

Within the first five seconds of a recent Ozempic commercial, a sky-blue injector pen tumbles toward the viewer, encircled by a big red O. Obesity drugs have become so closely associated with injections that the two are virtually synonymous. Like Ozempic, whose name is now a catchall term for obesity drugs, Wegovy and Zepbound come packaged in Sharpie-like injection pens that patients self-administer once a week.

One night in July, a few weeks after my son was born, I lay awake, desperately scrolling through photos of injured feet. The mounting pain from an ingrown toenail in my right foot had become excruciating, and the internet promised to help. I could no longer deny the fact that the exorbitantly expensive Hoka sneakers I’d bought just months before—to prevent pregnancy-related foot pain—had become too small. To my horror, my feet had grown half a size. Permanently.

If anything defines America’s current obesity-drug boom, it’s this: Many more people want these injections than can actually get them. The roadblocks include exorbitant costs that can stretch beyond $1,000 a month, limited insurance coverage, and constant supply shortages. But before all of those issues come into play, anyone attempting to get a prescription will inevitably confront the same obstacle: their body mass index, or BMI.

A wild idea recently circulated about the future of aviation: If passengers lose weight via obesity drugs, airlines could potentially cut down on fuel costs. In September, analysts at Jefferies Bank estimated that in the “slimmer society” obesity drugs will create, United Airlines could save up to $80 million in jet fuel annually.

On a recent visit to the supermarket, I found myself terribly disturbed by a carton of fruit. There, among the raspberries and blueberries, were ghostly white strawberries. They were the inverse of every strawberry I had ever seen—fully ripe berries with pale flesh bleeding pinpricks of red. Their seeds called to mind clogged pores in need of a nose strip. Rattled, I pivoted my cart toward less haunting produce.

Harvesting wild local produce in Brooklyn’s Prospect Park may not seem like the best idea. And yet, on a foraging tour of the lively public park last month, a straw-hatted forager named “Wildman” Steve Brill and his teenage daughter, Violet, led roughly 40 of us amateurs into the grassy areas beyond the park’s paved footpaths for a four-hour tromp.

Somehow, America’s desire for Ozempic is only growing. The drug’s active ingredient, semaglutide, is sold as an obesity medication under the brand name Wegovy—and it has become so popular that its manufacturer, Novo Nordisk, recently limited shipments to the U.S. and paused advertising to prevent shortages. Its promise has enticed would-be patients and set off a pharmaceutical arms race to create more potent drugs.

All of a sudden, Ozempic is everywhere. The weight-loss drug that it contains, semaglutide, is a potent treatment for obesity, and Hollywood and TikTok celebrities have turned it into a sensation. In just a few months, the medication has been branded as “revolutionary” and “game-changing,” with the power to permanently alter society’s conceptions of fatness and thinness.

On Tuesday, two men at a museum in the Netherlands lifted a black sheet off a table to reveal a cantaloupe-size globe of overcooked meat perspiring under a bell jar. This was no ordinary spaghetti topper: It was a woolly-mammoth meatball, created by an Australian lab-grown-meat company called Vow.

You overhear a lot of strange things in coffee shops, but an order for an “almond-based dairy-alternative cappuccino” is not one of them. Ditto a “soy-beverage macchiato” or an “oat-drink latte.” Vocalizing such a request elicited a confidence-hollowing glare from my barista when I recently attempted this stunt in a New York City café. To most people, plant-based milk is plant-based milk.

Bird flu, at this point, is somewhat of a misnomer. The virus, which primarily infects birds, is circulating uncontrolled around much of the world, devastating not just birds but wide swaths of the animal kingdom. Foxes, bobcats, and pigs have fallen ill. Grizzly bears have gone blind. Sea creatures, including seals and sea lions, have died in great numbers.But none of the sickened animals has raised as much concern as mink.

For many Americans, wearing a mask has become a relic. But fighting about masks, it seems, has not.Masking has widely been seen as one of the best COVID precautions that people can take. Still, it has sparked ceaseless arguments: over mandates, what types of masks we should wear, and even how to wear them. A new review and meta-analysis of masking studies suggests that the detractors may have a point.

I grew up in a nonstick-pan home. No matter what was on the menu, my dad would reach for the Teflon-coated pan first: nonstick for stir-fried vegetables, for reheating takeout, for the sunny-side-up eggs, garlic fried rice, and crisped Spam slices that constituted breakfast. Nowadays, I’m a much fussier cook: A stainless-steel pan is my kitchen workhorse.

These days, strolling through downtown New York City, where I live, is like picking your way through the aftermath of a party. In many ways, it is exactly that: The limp string lights, trash-strewn puddles, and splintering plywood are all relics of the raucous celebration known as outdoor dining.

Over the past week, my breakfast routine has been scrambled. I have had overnight oats, beans on sourdough, corned-beef hash and fried rice, and, on a particularly weird morning, leftover cream-of-broccoli soup. Under normal circumstances, I would be eating eggs. But right now, I’m in hoarding mode, jealously guarding the four that remain from a carton purchased indignantly for six dollars. For that price—50 damn cents each!—my daily sunny-side-up eggs will have to wait.

Cases have surged in China since it dropped its zero-COVID policy in December, and the latest models now suggest that at least 1 million people may die as a result. Many countries have responded by policing their borders: Last week, the CDC announced that anyone entering the United States from China would be required to test negative within two days of departure; the U.K., Canada, and Australia quickly followed suit; and the European Union has urged its member states to do the same.

No country has a perfect COVID vaccination rate, even this far into the pandemic, but America’s record is particularly dismal. About a third of Americans—more than a hundred million people—have yet to get their initial shots. You can find anti-vaxxers in every corner of the country.

No country has a perfect COVID vaccination rate, even this far into the pandemic, but America’s record is particularly dismal. About a third of Americans—more than a hundred million people—have yet to get their initial shots. You can find anti-vaxxers in every corner of the country.

This past spring, Amanda Goldberg crouched in the leafy undergrowth of a southwestern Virginia forest and attempted to swab a mouse for COVID. No luck; its nose was too tiny for her tools. “You never think about nostrils until you start having to swab an animal,” Goldberg, a conservation biologist at Virginia Tech University, told me.

When I called the epidemiologist Denis Nash this week to discuss the country’s worsening COVID numbers, he was about to take a rapid test. “I came in on the subway to work this morning, and I got a text from home,” Nash, a professor at the City University of New York, told me. “My daughter tested positive for COVID.”Here we go again: For the first time in several months, another wave seems to be on the horizon in the United States.

Two questions immediately occur to anyone watching the trailer for Cocaine Bear: Is this real? and Why? The first is easy enough to answer. The film, about a black bear who gobbles bricks of cocaine and then butchers a series of humans in rapid succession, is loosely based on a real-life black bear who, in 1985, gobbled at least part of a single brick of cocaine and then died.The true story had no murderous rampage.

For refrigerators across America, the passing of Thanksgiving promises a major purge. The good stuff is the first to go: the mashed potatoes, the buttery remains of stuffing, breakfast-worthy cold pie. But what’s that in the distance, huddled gloomily behind the leftovers? There lie the marginalized relics of pre-Thanksgiving grocery runs. Heavy cream, a few days past its sell-by date. A desolate bag of spinach whose label says it went bad on Sunday.

By this point, the pandemic saga has introduced us to a cast of recurring characters. Among them are the Chill Friend, who is totally over COVID precautions at this point, and the Unlucky Acquaintance, who has had COVID three times and brings it up whenever someone else falls sick. And then there is the Person Whose Roommate Has COVID.

I am on a mission to preserve the most valuable item in my home: my fiancé, who has never had COVID. Through sheer luck and a healthy dose of terror, he made it through the first pandemic year without getting sick. Shielded by the J&J vaccine and a Moderna booster, he dodged infection when I fell ill last November and coughed up the coronavirus all over our cramped New York City apartment.

In mid-March, I began to notice a theme within my social circle in New York, where I live: COVID—it finally got me! At that point, I didn’t think much of it. Only a few of my friends seemed to be affected, and case counts were still pretty low, all things considered. By April, images of rapid tests bearing the dreaded double bars were popping up all over my Instagram feed. Because cases had been rising slowly but steadily, I dismissed the trend to the back of my mind.

In mid-March, I began to notice a theme within my social circle in New York, where I live: COVID—it finally got me! At that point, I didn’t think much of it. Only a few of my friends seemed to be affected, and case counts were still pretty low, all things considered. By April, images of rapid tests bearing the dreaded double bars were popping up all over my Instagram feed. Because cases had been rising slowly but steadily, I dismissed the trend to the back of my mind.

Over the past month, the number of new COVID cases in my social circle has become impossible to ignore. I brushed off the first few—guests at a wedding I attended in early April—as outliers during the post-Omicron lull. But then came frantic texts from two former colleagues. The next week, a friend at the local café was complaining that she’d lost her sense of smell. My Instagram feed is now surfacing selfies of people in isolation, some for the second or third time.

Well, here we are again. After our fleeting brush with normalcy during Omicron’s retreat, another very transmissible new version of the coronavirus is on the rise—and with it, a fresh wave of vacillation between mask-donning and mask-doffing.The Omicron offshoot BA.2 is now the dominant variant around the world and in the United States. Case counts are rising in a number of states. It’s too early to tell whether BA.

Well, here we are again. After our fleeting brush with normalcy during Omicron’s retreat, another very transmissible new version of the coronavirus is on the rise—and with it, a fresh wave of vacillation between mask-donning and mask-doffing.The Omicron offshoot BA.2 is now the dominant variant around the world and in the United States. Case counts are rising in a number of states. It’s too early to tell whether BA.